Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LOC-paclitaxel
- Development stage
- Discontinued
- Lead developer
- American Regent
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
LOC-paclitaxel is an investigational cationic liposomal formulation of the taxane chemotherapy agent paclitaxel, developed by the M.D. Anderson Cancer Center. It was designed to improve the therapeutic index of paclitaxel by utilizing a cationic liposomal delivery system (Liposome-Occluded-Cationic) that targets the tumor neovasculature. Cationic liposomes have a high affinity for the negatively charged surface of activated endothelial cells in angiogenic vessels. Upon delivery, the active ingredient, paclitaxel, binds to the beta-subunit of tubulin, stabilizing microtubules and preventing their disassembly. This interference with microtubule dynamics leads to cell cycle arrest at the G2/M phase and induces apoptosis. The formulation was specifically evaluated in Phase I clinical trials for patients with metastatic melanoma to determine the maximum tolerated dose and safety profile.
- Other names
- Liposomal-cationic paclitaxelCationic liposomal paclitaxelLiposome-Occluded-Cationic paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on LOC-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LOC-paclitaxel.